Keyphrases
Long-term Efficacy
100%
Boosted Protease Inhibitors
100%
Europe
100%
Antiretroviral Therapy
100%
Ritonavir
62%
Protease Inhibitors
62%
Lopinavir
62%
Atazanavir
62%
Darunavir
62%
Virological Failure
50%
Viral Load
37%
Treatment Experience
37%
Nave
25%
Log-rank Test
12%
Separation Analysis
12%
Load Estimation
12%
Treatment Switch
12%
Cox Model
12%
Failure Risk
12%
June 2013
12%
Intention-to-treat
12%
Confounding by Indication
12%
Long-term Response
12%
Potential Confounders
12%
EuroSIDA
12%
Kaplan-Meier
12%
Multivariable
12%
Ritonavir-boosted Protease Inhibitors
12%
RNA Copies
12%
HIV RNA
12%
Treatment-experienced Patients
12%
Medicine and Dentistry
Proteinase Inhibitor
100%
Antiretroviral Therapy
100%
Darunavir Plus Ritonavir
85%
Atazanavir Plus Ritonavir
85%
Lopinavir/Ritonavir
71%
Log Rank Test
14%
Proportional Hazards Model
14%
Human immunodeficiency virus
14%
Intention-to-Treat Analysis
14%
Ritonavir
14%
Pharmacology, Toxicology and Pharmaceutical Science
Proteinase Inhibitor
100%
Atazanavir Plus Ritonavir
85%
Darunavir Plus Ritonavir
85%
Lopinavir Plus Ritonavir
71%
Ritonavir
14%
HIV
14%
Neuroscience
Proteinase
100%
Ritonavir
100%
Darunavir
45%
Lopinavir/Ritonavir
45%
Atazanavir
45%
Human immunodeficiency virus
9%
Nursing and Health Professions
Darunavir Plus Ritonavir
85%